Nutriband Inc. (NTRB)

NASDAQ: NTRB · IEX Real-Time Price · USD
4.520
+0.470 (11.60%)
At close: Mar 28, 2024, 4:00 PM
4.990
+0.470 (10.40%)
After-hours: Mar 28, 2024, 7:58 PM EDT
11.60%
Market Cap 34.26M
Revenue (ttm) 2.09M
Net Income (ttm) -5.28M
Shares Out 7.83M
EPS (ttm) -0.67
PE Ratio n/a
Forward PE 370.37
Dividend n/a
Ex-Dividend Date n/a
Volume 630,258
Open 4.250
Previous Close 4.050
Day's Range 4.180 - 5.927
52-Week Range 1.530 - 5.922
Beta 0.33
Analysts n/a
Price Target n/a
Earnings Date Apr 25, 2024

About NTRB

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agre... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Gareth Sheridan
Employees 13
Stock Exchange NASDAQ
Ticker Symbol NTRB
Full Company Profile

Financial Performance

In 2022, Nutriband's revenue was $2.08 million, an increase of 46.23% compared to the previous year's $1.42 million. Losses were -$4.48 million, -29.65% less than in 2021.

Financial Statements

News

Nutriband Announces Data Supporting Need for Safer Abuse-Deterrent Transdermal Patches Presented at 2024 American Academy of Pain Medicine Annual Meeting

Data highlights the incidence of abuse and accidental pediatric exposure of transdermal patches containing opioid and stimulant drugs Nutriband's AVERSA™ technology addresses the unmet need for safer ...

4 days ago - Accesswire

Prescription Transdermal Patch Abuse and Accidental Pediatric Exposure Remains a Serious Problem in the United States - Surveillance Data to Be Presented at 2024 American Academy of Pain Medicine Annual Meeting

ORLANDO, FL / ACCESSWIRE / March 4, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that da...

25 days ago - Accesswire

Nutriband Inc. to Present at The Microcap Conference Atlantic City January 30th through February 1st

Nutriband Inc. to Present at The Microcap Conference Atlantic City January 30th through February 1st. ORLANDO, FL / ACCESSWIRE / January 29, 2024 / Nutriband Inc. (Nasdaq:NTRB)(Nasdaq:NTRBW) today ann...

2 months ago - Accesswire

Nutriband CEO Publishes Letter to Shareholders

ORLANDO, FL / ACCESSWIRE / January 26, 2024 / Nutriband Inc. ("Company") (NASDAQ:NTRB)(NASDAQ:NTRBW) today announced that CEO Gareth Sheridan has published a letter to shareholders providing insights ...

2 months ago - Accesswire

Nutriband Inc. Expands its AI Kinesiology Tape Portfolio with the Launch of AI Tape Heating and Cooling

ORLANDO, FL / ACCESSWIRE / November 28, 2023 / Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced the launch of its new Heating and Coolin...

4 months ago - Accesswire

Nutriband Inc. Signs Supplier Agreement With KT Tape, the World Leader in Kinesiology Tape

ORLANDO, FL / ACCESSWIRE / November 8, 2023 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), today announced that it has signed a supplier agreement with market leading kinesiology tape company, KT Tape....

5 months ago - Accesswire

Nutriband's Aversa(TM) Buprenoprhine May Reach Peak Annual Sales of $70-130 Million Based on Market Assessment by Leading Healthcare Consulting Firm

ORLANDO, FL / ACCESSWIRE / October 11, 2023 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of transdermal pharmaceutical products, today announced it has completed ...

6 months ago - Accesswire

Nutriband Announces Issuance of U.S. Patent for Transdermal Abuse Deterrent Technology

Patent issuance expands U.S. patent portfolio for AVERSA™ transdermal abuse deterrent technology ORLANDO, FL / ACCESSWIRE / September 20, 2023 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a developer...

6 months ago - Accesswire

Nutriband Inc. Receives Five Nominations in the Pharma Industry Awards 2023

Nominations recognize innovative development of AVERSA™ abuse-deterrent transdermal technology ORLANDO, FL / ACCESSWIRE / September 12, 2023 / Nutriband Inc. (the "Company") (NASDAQ:NTRB)(NASDAQ:NTRBW...

7 months ago - Accesswire

Nutriband Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update

Second quarter 2023 revenues increased 48% compared to second quarter 2022 ORLANDO, FL / ACCESSWIRE / September 11, 2023 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharma...

7 months ago - Accesswire

Nutriband Inc. Announces Donovan McNabb as AI Tape Brand Ambassador

AI Tape has potential to tap into the $236 million Elastic Therapeutic Tape market ORLANDO, FL / ACCESSWIRE / August 30, 2023 / Nutriband Inc. (the "Company") (NASDAQ:NTRB)(NASDAQ:NTRBW), a developer ...

7 months ago - Accesswire

Nutriband Inc. Launches AI Tape Brand Direct-to Consumer Offerings

ORLANDO, FL / ACCESSWIRE / July 27, 2023 / Nutriband Inc. (the "Company") (NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced the launch of its consumer sp...

8 months ago - Accesswire

Nutriband Increases Existing Credit Line to $5 Million USD for the Development of its AVERSA(TM) Platform Towards FDA Submission

Company targeting FDA submission in the first half of 2024 AVERSA ™ Fentanyl is the flagship product of the Company's AVERSA™ Platform ORLANDO, FL / ACCESSWIRE / July 14, 2023 / Nutriband Inc. ("Compa...

9 months ago - Accesswire

Nutriband Receives Notice of Allowance for U.S. Patent Covering Transdermal Abuse Deterrent Technology

ORLANDO, FL / ACCESSWIRE / June 23, 2023 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced that it received a Notice of Allowance from t...

10 months ago - Accesswire

Nutriband to Attend 2023 BIO International Convention

ORLANDO, FL / ACCESSWIRE / May 10, 2023 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced that it will be attending the Biotechnology In...

11 months ago - Accesswire

Nutriband Inc. Reports Revenue Up 46% in Fiscal 2023

ORLANDO, FL / ACCESSWIRE / April 27, 2023 / Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced financial and operational results for the f...

1 year ago - Accesswire

Nutriband Inc. to Present at the Planet MicroCap Showcase: VEGAS 2023 on Wednesday, April 26, 2023

ORLANDO, FL / ACCESSWIRE / April 19, 2023 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a pioneer in the development of innovative transdermal solutions, today announced that it will be presenting at ...

1 year ago - Accesswire

Nutriband Secures $2 Million Line of Credit Financing Facility to be Used for Commercialization of AVERSA(TM) Abuse-Deterrent Transdermal Technology

ORLANDO, FL / ACCESSWIRE / March 28, 2023 / Nutriband Inc. ("Company") (NASDAQ:NTRB)(NASDAQ:NTRBW) has entered into a three-year $2,000,000 Credit Line facility to provide financing through the FDA ap...

1 year ago - Accesswire

Nutriband Inc Joins Webull Corporate Communications Service Platform

ORLANDO, FL / ACCESSWIRE / March 8, 2023 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) announced that it has joined Webull's Corporate Communications Service Platform, which will provide Nutriband with...

1 year ago - Accesswire

Nutriband COO Alan Smith Ph.D. Selected for FDA Center for Research on Complex Generics Stakeholder Expert Committee

ORLANDO, FL / ACCESSWIRE / March 2, 2023 / Nutriband Inc. (the "Company") (NASDAQ:NTRB)(NASDAQ:NTRBW) today announced that Alan Smith, Ph.D., Chief Operating Officer (COO), Nutriband, and President of...

1 year ago - Accesswire

Nutriband Inc. to File for Product Distribution Permit in South America with Ecuador's Health Register

ORLANDO, FL / ACCESSWIRE / February 15, 2023 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) today announced that its has completed the requirements to file its application with Ecuador's Health Register...

1 year ago - Accesswire

Nutriband Inc. to Present at the 2023 Transdermal and Microneedle Conference

ORLANDO, FL / ACCESSWIRE / January 24, 2023 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a pioneer in the science of using novel transdermal solutions and other innovative technologies, today announc...

1 year ago - Accesswire

Nutriband Inc. Commences Trading on Upstream Under NTRB

Nutriband among the first issuers to dual list on Upstream ORLANDO, FL / ACCESSWIRE / January 5, 2023 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a pioneer in the science of using novel transdermal ...

1 year ago - Accesswire

Nutriband Inc. Will Be the First Company to Dual List on Upstream

Trading scheduled to Commence on Upstream January 5, 2023 ORLANDO, FL / ACCESSWIRE / December 30, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) announced today that it will be the first company to...

1 year ago - Accesswire

Nutriband Inc. to Officially Launch AI Tape brand in Q1 2023

ORLANDO, FL / ACCESSWIRE / December 29, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) announced today that it has begun production of its AI Tape brand with an expected launch of the product line ...

1 year ago - Accesswire